FDA WARNING_LETTER - Amneal Pharmaceuticals, Llc - March 19, 2025

Amneal Pharmaceuticals Private Limited, located in Gujarat, India, was inspected by the FDA from March 10 to 19, 2025. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals, as outlined in Title 21 CFR parts 210 and 211. The primary issue identified was the firm"s failure to adequately investigate and address recurring particulate matter contamination in sterile injectable products, specifically ropivacaine hydrochloride injections. The contamination was traced to defective polypropylene bags, yet the company continued their use without implementing effective corrective actions.

The FDA found that Amneal"s risk assessment minimized the severity of potential health risks associated with particulate contamination, particularly in epidural injections, which could lead to serious conditions such as meningitis or spinal cord damage. Despite being aware of these risks since late 2022, Amneal failed to take appropriate preventive measures and instead relaxed their quality acceptance criteria to accommodate the defective bags.

Additionally, the firm did not establish adequate laboratory controls to ensure product quality, with deficiencies noted in bacterial endotoxin testing procedures. Although Amneal initiated a recall of affected batches and revised some procedures post-inspection, the FDA deemed these responses insufficient.

The FDA requires Amneal to provide a comprehensive plan to address these violations, including revising defect limits, enhancing visual inspection methods, and ensuring top management supports quality assurance efforts. The company must ensure preventive measures are integrated into production processes to maintain product integrity and patient safety.